Mother looking in mirror at two teenagers

Combating Meningococcal Disease in Vulnerable Populations

Pfizer's vaccines, Nimenrix® (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) and Trumenba® (Meningococcal Group B Vaccine), help provide countries and health care providers with the ability to broadly protect against this uncommon disease that is unpredictable and potentially deadly. We continue to build Nimenrix manufacturing capabilities with investment in our manufacturing sites. In many parts of the world, Nimenrix is indicated from two months of age.

We also made significant progress in expanding the reach of Trumenba, with launches across the globe. This broader availability reinforces Pfizer's dedication to advancing important vaccines that can help protect adolescents and adults.

Go back

Explore Our Innovation